Hyperlipoproteinemias:
Indications for NEXLIZET:
An adjunct to diet and maximally tolerated statin therapy, in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use:
The effect on cardiovascular morbidity and mortality has not been determined.
Adult Dosage:
Swallow whole. 180mg/10mg once daily. After initiation, assess lipid levels within 8–12 weeks. Concomitant bile acid sequestrants: give Nexlizet either ≥2hrs before or ≥4hrs after.
Children Dosage:
Not established.
NEXLIZET Warnings/Precautions:
Hyperuricemia. Assess serum uric acid as clinically indicated. History of gout. Increased risk for tendon rupture/injury (esp. >60yrs, in those taking corticosteroid or fluoroquinolone drugs, renal failure, previous tendon disorders); consider discontinuing if joint pain, swelling, or inflammation develop. History of tendon disorders/rupture: consider alternative therapy. Elderly. Moderate or severe hepatic (Child-Pugh B or C): not recommended. Severe renal impairment (eGFR <30mL/min/1.73 m2). ESRD on dialysis. Pregnancy, nursing mothers: not recommended.
NEXLIZET Classification:
Adenosine triphosphate-citrate lyase (ACL) inhibitor + cholesterol absorption inhibitor.
NEXLIZET Interactions:
Avoid concomitant simvastatin >20mg or pravastatin >40mg. Concomitant cyclosporine increases ezetimibe and cyclosporine levels; monitor. Concomitant use with fibrates (except fenofibrate): not recommended. Concomitant use with fenofibrate: consider alternative therapy if cholelithiasis is suspected. Antagonized by cholestyramine (see Adult dose).
Adverse Reactions:
Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, arthralgia, sinusitis, fatigue, influenza; BPH, atrial fibrillation, hypersensitivity reactions (ezetimibe).
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
